Journal
MOLECULAR THERAPY-NUCLEIC ACIDS
Volume 7, Issue -, Pages 211-222Publisher
CELL PRESS
DOI: 10.1016/j.omtn.2017.04.001
Keywords
-
Categories
Funding
- [128,014-PN-II-PT-PCCA-2013-4-2166]
- [35/01.09.2016]
- [37_796]
- MRC [G0701159] Funding Source: UKRI
- Medical Research Council [G0701159] Funding Source: researchfish
Ask authors/readers for more resources
With the expansion of the microbiology field of research, a new genome editing tool arises from the biology of bacteria that holds the promise of achieving precise modifications in the genome with a simplicity and versatility that surpasses previous genome editing methods. This new technique, commonly named CRISPR/Cas9, led to a rapid expansion of the biomedical field; more specifically, cancer characterization and modeling have benefitted greatly from the genome editing capabilities of CRISPR/Cas9. In this paper, we briefly summarize recent improvements in CRISPR/Cas9 design meant to overcome the limitations that have arisen from the nuclease activity of Cas9 and the influence of this technology in cancer research. In addition, we present challenges that might impede the clinical applicability of CRISPR/Cas9 for cancer therapy and highlight future directions for designing CRISPR/Cas9 delivery systems that might prove useful for cancer therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available